(Q40515435)

21 September 2017

title

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. (English)

1 reference

idiopathic pulmonary fibrosis

21 September 2017

1 reference

1 reference

3

Luca Richeldi

1 reference

21 September 2017

1

Ulrich Costabel

1 reference

21 September 2017

Yoshikazu Inoue

2

1 reference

21 September 2017

Harold R Collard

4

1 reference

21 September 2017

Inga Tschoepe

5

1 reference

21 September 2017

Susanne Stowasser

6

1 reference

21 September 2017

Arata Azuma

7

1 reference

21 September 2017

language of work or name

English

0 references

publication date

22 September 2015

1 reference

American Journal of Respiratory and Critical Care Medicine

21 September 2017

published in

1 reference

21 September 2017

volume

193

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

178-185

1 reference

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

Gender influences Health-Related Quality of Life in IPF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201503-0562OC

10.1164/RCCM.201503-0562OC

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference